Welcome to our dedicated page for Adaptimmune Therapeutics Plc news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics Plc stock.
Adaptimmune Therapeutics plc (ADAP) generates a steady flow of news centered on its work in engineered T cell receptor (TCR) cell therapies for solid tumor cancers. Company announcements cover clinical progress, regulatory milestones, commercial activity, strategic transactions and corporate restructuring, providing context for how its business and ADAP stock have evolved over time.
Recent news highlights include the launch and commercial metrics for TECELRA, an engineered T-cell therapy that Adaptimmune describes as the first such therapy approved in the U.S. for a solid tumor cancer, as well as pivotal trial results and regulatory plans for lete-cel in synovial sarcoma and myxoid/round cell liposarcoma. Releases detail Authorized Treatment Center activation, patient aphereses, invoiced doses and manufacturing performance, giving readers insight into how the company has executed on its sarcoma franchise.
Investors following ADAP news will also find coverage of Adaptimmune’s definitive agreement and subsequent transaction with US WorldMeds, under which the company sold the assets and rights related to Tecelra, lete-cel, afami-cel and uza-cel. These stories explain the upfront and potential milestone payments, transfer of employees, and associated transition and license agreements. Additional updates describe the repayment of debt to Hercules Capital and the company’s efforts to maximize value from remaining preclinical assets such as PRAME- and CD70-directed programs.
Other Adaptimmune news items focus on Nasdaq listing compliance notices, the Board’s decision to voluntarily delist the company’s ADSs from The Nasdaq Capital Market and pursue deregistration, and the expectation that trading may move to an over-the-counter market. Executive leadership changes, headcount reductions, cost-saving initiatives and going concern disclosures are also covered. For readers tracking ADAP, this news page brings together financial results, regulatory filings, scientific conference presentations and strategic updates in one place.
The Phase 1 SURPASS trial presented by Adaptimmune Therapeutics (Nasdaq: ADAP) highlighted the efficacy of AKT inhibitors (AKTi) in enhancing SPEAR T-cell products. The addition of AKTi during ex vivo manufacturing improved T-cell proliferation and memory phenotype, leading to better antitumor responses. Notably, ADP-A2M4CD8 SPEAR T-cells displayed higher median persistence in patients, suggesting robust immune response potential. Results from the radiation sub-study indicated a disease control rate of 100%, underscoring the promising therapeutic effects of afami-cel.
Adaptimmune Therapeutics (ADAP) announced that its SPEARHEAD-1 trial has met its primary endpoint, with an overall response rate (ORR) of 34% in patients treated with afami-cel. This data will support a Biologics License Application (BLA) filing next year. The disease control rate stands at 85%, with a favorable benefit:risk profile observed. Translational data confirm afami-cel's efficacy against MAGE-A4 expressing targets both in vitro and in vivo.
Adaptimmune Therapeutics plc (ADAP) announced a strategic collaboration with Genentech, receiving a $150 million upfront payment. The SURPASS trial data presented at ESMO shows a 36% overall response rate and an 86% disease control rate across various solid tumors. The company has initiated the Phase 2 SURPASS-2 trial for esophageal and EGJ cancers and plans to begin SURPASS-3 for ovarian cancer in 2022. Financial results reveal a net loss of $42.4 million for Q3, while cash and liquidity are sufficient to fund operations into early 2024.
Deep Genomics has appointed Tal Zaks, MD, PhD, former CMO of Moderna, to its Strategic Advisory Board. Zaks brings valuable experience from leading mRNA vaccine development, including Moderna’s COVID-19 vaccine. This move aims to bolster Deep Genomics' mission to create programmable medicines through its advanced AI Workbench platform. With a recent $180 million funding, the company plans to expand its pipeline significantly, targeting thirty AI-discovered programs by 2024, while enhancing its research capabilities in Toronto and Cambridge.
Adaptimmune Therapeutics (Nasdaq:ADAP) plans to announce its third-quarter financial results for the period ending September 30, 2021, on November 4, 2021, prior to U.S. market opening. A live teleconference and webcast will follow at 8:00 a.m. EDT. The press release and webcast will be accessible via the investor section of the company’s website. Adaptimmune is focused on developing innovative cancer immunotherapy products using its unique SPEAR T-cell platform, targeting multiple solid tumors. This announcement comes with forward-looking statements regarding potential risks and uncertainties.
Adaptimmune Therapeutics (Nasdaq: ADAP) will present key clinical and translational data from its Phase 2 SPEARHEAD-1 trial at the CTOS meeting. This includes data crucial for their upcoming BLA submission for afami-cel targeting synovial sarcoma and MRCLS. They will also share findings from the Phase 1 SURPASS trial at the SITC meeting. Noteworthy presentations include an oral session by Dr. Brian Van Tine and a virtual symposium on November 11, 2021, emphasizing advancements in T-cell therapies.
Adaptimmune Therapeutics (NASDAQ: ADAP) announced promising outcomes from its Phase 1 SURPASS trial, demonstrating significant anti-tumor activity across various cancers. Key findings include a 36% overall response rate and an 86% disease control rate, with a complete response reported in ovarian cancer. The ADP-A2M4CD8 therapy has displayed enhanced tumor cell killing and improved immune system engagement. The company is actively recruiting patients for this and a new Phase 2 trial targeting esophageal and EGJ cancers, indicating progress towards late-stage development.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) has announced a strategic collaboration with Genentech to develop allogeneic cell therapies for cancer. This agreement entails an upfront payment of $150 million, with an additional $150 million expected over five years, and potential milestone payments exceeding $3 billion. Adaptimmune will utilize its induced pluripotent stem cell (iPSC) platform for T-cell production, while Genentech will focus on TCR input and clinical development. The partnership is subject to clearance under antitrust laws and aims to broaden personalized cancer treatment approaches.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) presented updated data from its Phase 1 ADP-A2AFP trial for liver cancer at the International Liver Cancer Association meeting. The trial showed a disease control rate of 64%, with one patient achieving a complete response and two patients maintaining stable disease for over 16 weeks. The safety profile was deemed acceptable, with no significant hepatotoxicity reported. The ongoing expansion phase aims to treat up to 25 patients, suggesting continued potential for this cell therapy approach in advanced hepatocellular carcinoma.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) reported its Q2 2021 results, highlighting an overall response rate of 39.3% in synovial sarcoma from its SPEARHEAD-1 trial. The company plans to submit a Biologics License Application (BLA) for afami-cel next year. Revenue for Q2 was $3.1 million, a significant increase from $0.5 million in Q2 2020, driven by collaboration activities. However, R&D expenses rose to $28.9 million, leading to a net loss of $39.1 million. The company expects to be funded into early 2023.